Narrows FY23 gross profit margin to within 68%-68.5% from 68%-69% . Narrows FY23 operating expense to 12%-14% from 12%-15%. Sees FY23 capital expenditures $900M-$1B. Sees FY23 tax rate 22%-23%. Says in the short term will see patients that are considering bariatric surgery will try GLP1 drugs, but will not stay on the drugs long term and then consider bariatric surgeries after. Guidance taken from Q3 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ISRG: